{"id":46829,"date":"2014-11-26T13:46:11","date_gmt":"2014-11-26T18:46:11","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/psoriasis-drug-trial-meets-goals-reimbursement-rate-for-cologuard-finalized\/"},"modified":"2014-11-26T13:46:11","modified_gmt":"2014-11-26T18:46:11","slug":"psoriasis-drug-trial-meets-goals-reimbursement-rate-for-cologuard-finalized","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/psoriasis-drug-trial-meets-goals-reimbursement-rate-for-cologuard-finalized\/","title":{"rendered":"Psoriasis Drug Trial Meets Goals, Reimbursement Rate For Cologuard Finalized"},"content":{"rendered":"<p><p>    Amgen Inc. (AMGN: Quote) and AstraZeneca plc's (AZN: Quote) phase III trial of psoriasis drug    candidate Brodalumab has met its primary endpoint of achieving    total clearance of skin disease when compared with placebo as    well as Janssen Biotech Inc.'s approved drug Stelara.  <\/p>\n<p>    The trial, dubbed AMAGINE-2, is the third and final pivotal    study in the companies' phase III psoriasis program. Brodalumab    is being co-developed by Amgen and AstraZeneca.  <\/p>\n<p>    Top-line results from AMAGINE-1, comparing Brodalumab with    placebo, were released in May 2014 while top-line results from    AMAGINE-3, comparing Brodalumab with Stelara and placebo, were    announced as recently as November 11, 2014.  <\/p>\n<p>    The trials AMAGINE-2 and AMAGINE-3 are identical in design.  <\/p>\n<p>    AMGN closed Tuesday's trading at $162.24, down 1.18%.  <\/p>\n<p>    Exact Sciences Corp.'s (EXAS: Quote) Cologuard will be reimbursed at $502    per test, according to the final payment decision issued by the    Centers for Medicare & Medicaid Services.  <\/p>\n<p>    Cologuard is the first and only FDA-approved noninvasive stool    DNA colorectal cancer screening test.  <\/p>\n<p>    EXAS closed Tuesday's trading at $24.90, up 2.55%.  <\/p>\n<p>    Intra-Cellular Therapies Inc. (ITCI:    Quote) has enrolled the first patient in its    phase III trial of ITI-007 for the treatment of schizophrenia.  <\/p>\n<p>    The trial, dubbed ITI-007-301, is designed to enroll over 400    patients with an acutely exacerbated episode of schizophrenia    who will be randomized to receive one of three treatments    namely, 60 mg ITI-007, 40 mg ITI-007, or placebo in a 1:1:1    ratio. Top-line results from this trial could be available as    early as the fourth quarter of 2015.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Continued here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.rttnews.com\/story.aspx?Id=2422356\/RK=0\/RS=DMW3UGn_DEiOhWJ.xq8LFPhQgKs-\" title=\"Psoriasis Drug Trial Meets Goals, Reimbursement Rate For Cologuard Finalized\">Psoriasis Drug Trial Meets Goals, Reimbursement Rate For Cologuard Finalized<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Amgen Inc. (AMGN: Quote) and AstraZeneca plc's (AZN: Quote) phase III trial of psoriasis drug candidate Brodalumab has met its primary endpoint of achieving total clearance of skin disease when compared with placebo as well as Janssen Biotech Inc.'s approved drug Stelara <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/psoriasis-drug-trial-meets-goals-reimbursement-rate-for-cologuard-finalized\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-46829","post","type-post","status-publish","format-standard","hentry","category-psoriasis"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/46829"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=46829"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/46829\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=46829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=46829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=46829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}